Investors

Eurocine Vaccines is publically listed at Spotlight Stock Market XSAT, Sweden, with the ticker EUCI.

To be notified with news, sign up to our newsfeed =>

Legal Advisor is Lindahl and MCL.

Sedermera is our Financial Advisor.

Patent and Intellectual Property (IP) advisors are Zacco and AWA.

Preferential Unit Issue / Företrädesemission

Eurocine Vaccines gästade Småbolagspodden / Eurocine Vaccines visited the Small Companies´ pod

I samband med den pågående företrädesemission så gästade Eurocine Vaccines vd Hans Arwidsson Småbolagspodden för att berätta mer om bolagets senaste strategiska förändring och utvecklingen av den terapeutiska vaccinkandidaten mot Herpes simplexvirus typ 2 (HSV-2). Lyssna på Eurocine Vaccines i Småbolagspodden !

In connection with the ongoing rights issue, Eurocine Vaccines CEO Hans Arwidsson visited the Småbolagspodden to tell more about the company’s latest strategic change and the development of the therapeutic vaccine candidate against Herpes simplex virus type 2 (HSV-2). Listen to Eurocine Vaccines in the Small Companies´ pod (in Swedish)!

Read the Memorandum and the Teaser!

Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of units, up to cirka 7.5 MSEK before issue costs. The subscription period begins Tuesday 9 January 2024.

Eurocine Vaccines´ Memorandum 2024 (in Swedish)

Eurocine Vaccines´ Teaser – a short information brochure (in Swedish). Please read the Important information (Viktig information)!

Terms and conditions for warrants TO 5 – Villkor för teckningsoptioner TO 5 (in Swedish).

To subscribe in the present preferential issue /
För att teckna i pågående företrädesemission

Teckna units med digital signering här.

För att som befintlig ägare i bolaget via Avanza eller Nordnet anmäla intresse att delta i emissionen, följ nedanstående länkar:

För att anmäla intresse att teckna units via Nordnet, klicka här.

För att anmäla intresse att teckna units via Avanza, klicka här.

Annual General Meeting 29 December 2023

Below follow documents related to the Annual General Meeting on the 29 December 2023:

Notice (Kallelse, in Swedish)

Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)

Presentation of proposed board director (Presentation av föreslagen ledamot, in Swedish)

Annual Report 2022-2023 (Årsredovisning 2022-2023, in Swedish)

Proxy Form (Fullmaktsformulär, in Swedish)

Preferential Share Issue

Eurocine Vaccines AB publishes an Information Memorandum in connection with the Company´s preferential issue of shares up to cirka 9,7 MSEK before issue costs, which subscription period begins Wednesday 2 August 2023.

Eurocine Vaccines´ Memorandum 2023 (in Swedish)

Supplementary Memorandum 7 August 2023 (Tilläggsmemorandum, in Swedish)

Extraordinary General Meeting
26 July 2023

Below follow documents related to the Extraordinary General Meeting on the 26 July 2023:

Notice (Kallelse, in Swedish)

Complete Proposed Decisions (Fullständiga beslutsförslag, in Swedish)

Proxy Form (Fullmaktsformulär, in Swedish)



Latest Investor Presentation
CEO Dr. Hans Arwidsson presents at Aktieportföljen Live, 11 October 2022

Future Financial Reports

The Interim Report July – December 2023 is planned to be available 28 February 2024.


Existing Financial Reports

Interim Report July – September 2023

Annual Report 2022 – 2023 (Swedish)

Full Year Report July 2022 – June 2023

Interim Report July 2022 – March 2023

Interim Report July – December 2022

Interim Report July – September 2022

Full Year Report July 2021 – June 2022 =>

Interim Report July 2021 – March 2022 =>

Annual Review 2021 =>

Interim Report July – December 2021 =>

Interim Report July – September 2021 =>

Full Year Report July 2020 – June 2021 =>

Interim Report July 2020 – March 2021 =>

Half Year Report July – December 2020 =>

Interim Report July – September 2020 =>